Melanotan I Reconstitution: Measurement Education and What Studies Used

Melanotan I is the common informal name for afamelanotide, a synthetic analogue of α-melanocyte-stimulating hormone also written as Nle4-D-Phe7-α-MSH or NDP-MSH. Searches for "how to reconstitute melanotan 1" and "how to mix melanotan 1" are usually asking about a laboratory measurement problem: a sealed vial contains a freeze-dried solid, and someone wants to understand how that solid relates to a volume of liquid and to the marks printed on a syringe barrel. This page is for educational purposes only and is not medical advice; consult a licensed physician for any question about a medical condition, a medicine, or personal health. Nothing here states a quantity that any person should prepare, measure, or administer.

What "Reconstitution" Means as a Laboratory Term

Lyophilisation, or freeze-drying, removes water from a peptide solution under vacuum and leaves behind a dry cake or powder. The dried solid is far more stable in storage than a solution. Reconstitution is simply the reverse step: a liquid is added so that the solid dissolves and the material returns to solution form. The word describes a physical process and a unit-conversion problem, not a treatment plan.

Three quantities appear in every reconstitution discussion, and confusing them is the origin of most arithmetic errors:

The relationship between them is ordinary division: C = M ÷ V. Rearranged, the volume of solution that would contain a given mass is V = m ÷ C. These are the same two equations taught in any introductory chemistry unit on solution concentration, and they hold regardless of which substance is in the container.

Why the arithmetic is presented symbolically here

Plugging numbers into C = M ÷ V produces a concentration, and pairing a concentration with a volume produces a mass. Because that second step is indistinguishable from stating a dose, this page deliberately keeps the arithmetic in symbols. Readers who want to work through the division for a labelled container can use PeptideU's reconstitution calculator, which is a lab-math tool for unit conversion; it performs the same division shown above and does not recommend any quantity.

How Syringe Markings Map to Volume

A frequent source of confusion is that syringe barrels are not graduated in milligrams. They are graduated in volume. An insulin-style syringe described as "U-100" is manufactured so that the full barrel corresponds to one millilitre divided into one hundred equal graduations. The conversions below are fixed properties of the syringe's geometry and describe no substance and no quantity of any substance:

• The full barrel of a 1 mL U-100 syringe spans 100 graduations.
• Each single graduation therefore represents one hundredth of a millilitre.
• Half the barrel spans 50 graduations, which is half a millilitre.
• A syringe sold as a 0.5 mL U-100 barrel spans 50 graduations across its full length, so the marks are spaced further apart but each still represents the same volume.

Because the barrel reports volume, a concentration is always required to translate a graduation into a mass, and the concentration comes from the C = M ÷ V step above. Two vials reconstituted with different solvent volumes will produce different concentrations, so identical graduations on identical syringes would correspond to different masses. This is why concentration, not syringe marks, is the meaningful number in any laboratory record.

Tuberculin and low-dead-space barrels

Tuberculin-style syringes are graduated directly in decimal fractions of a millilitre rather than in units, which removes one conversion step. Dead space, the small volume retained in the hub and needle after the plunger bottoms out, is a manufacturing specification that differs between barrel designs and is another reason laboratory records generally document volumes measured, not marks counted.

Reading a Certificate of Analysis for Vial Contents

A certificate of analysis (COA) is the analytical document a manufacturer issues for a specific production lot. For reconstitution arithmetic, the relevant fields are the ones that describe what is actually in the container:

• Lot or batch identifier — the COA applies only to the lot it names, so matching the lot number on the vial to the document is the first check.
• Identity confirmation — usually mass spectrometry, reporting an observed molecular mass compared with the theoretical mass for the stated sequence.
• Purity — typically by reverse-phase HPLC, expressed as a percentage of the main chromatographic peak. Purity is a property of the solid, not of any solution made from it.
• Net peptide content — the fraction of the labelled mass that is peptide rather than counter-ions (commonly acetate or trifluoroacetate) and residual water. A vial can be labelled by gross fill mass while the peptide fraction is lower, which is why net peptide content matters to anyone reconciling a label with an analytical result.
• Water content — often by Karl Fischer titration, relevant because residual moisture contributes to the mass on the balance.
• Appearance and solubility notes — some COAs describe the expected appearance of the cake and the solvents in which the solid was found to dissolve during testing.

Material sold with a COA of this type is generally designated research use only (RUO). RUO labelling means the material has not been evaluated or approved as a medicine for administration to people, and that regulatory status is independent of whatever the COA reports about purity.

What Formulations the Published Melanotan I Studies Used

Readers looking for a "study protocol for mixing" in the peer-reviewed afamelanotide literature will find that the question does not map onto how the published work was done. The clinical development programme did not distribute dried powder for laboratory reconstitution; researchers worked with a finished, controlled-release formulation. Reviews of the pharmacokinetics and pharmacodynamics of afamelanotide described the clinical product as a bioresorbable subcutaneous implant that released the peptide over a period of days, and summarised how that delivery format shaped absorption and elimination, as reported in this 2017 review in Clinical Pharmacokinetics. A review in the American Journal of Clinical Dermatology similarly described the implant formulation in the context of erythropoietic protoporphyria (EPP) and the clinical outcomes reported for it (PMID 26979527).

Further reviews reached the same description of the delivery system. Coverage of afamelanotide for prevention of phototoxicity in EPP discussed the implant and the regulatory approval of the product for that indication (PMID 33507118), and earlier and later overviews of the melanocortin analogue in dermal phototoxicity described the same controlled-release approach (PMID 21073357, PMID 25470471). A 2024 review in Postępy Dermatologii i Alergologii surveyed protoporphyria and other dermatologic settings in which the agent has been studied (PMID 38784937), and a study of patients with Hailey-Hailey disease examined the melanocortin analogue Nle4-D-Phe7-α-MSH in that condition (PMID 24256215).

The practical consequence for a measurement page is straightforward: the verified clinical literature above does not specify a reconstitution solvent, a diluent volume, or a solution concentration, because reconstitution was not the delivery route those investigators used. Any claim that a particular solvent is "what the studies used" for melanotan I is therefore not supported by these papers. Descriptions of solvents such as bacteriostatic or sterile water belong to general laboratory and pharmacy practice literature rather than to the afamelanotide trial reports summarised here.

Concepts That Change the Arithmetic

Nominal label mass versus net peptide content

If a calculation uses the gross label mass while the COA reports a lower net peptide content, the computed concentration will overstate the peptide actually in solution. Laboratories that need accuracy generally decide in advance which figure their records use and state it explicitly.

Displacement and final volume

Adding solvent to a solid produces a final volume that is the solvent volume plus a small contribution from the dissolved solid. For small masses of peptide this displacement is usually treated as negligible, but the assumption is an assumption, and analytical work that requires precision measures the final volume rather than inferring it.

Vacuum, headspace and transfer losses

Lyophilised vials are often sealed under partial vacuum, which affects how liquid enters the container. Material left in the vial neck, on the stopper, or in syringe dead space is mass that never reached the solution or the measurement, and is a recognised source of discrepancy between calculated and measured concentrations.

Afamelanotide Adverse Events: What Studies Report

Because readers arriving at a reconstitution page often want to know what the clinical literature reported overall, the tolerability picture described in the reviews is summarised here without reference to any quantity. Reviews of afamelanotide in EPP reported that the adverse events described were generally mild, with nausea, headache and fatigue among those noted, alongside darkening of the skin consistent with the agent's melanogenic mechanism (PMID 26979527, PMID 33507118). A review of the drug's broader dermatologic potential likewise discussed its safety profile alongside the indications in which it has been investigated (PMID 33683075), and an overview of melanocyte-stimulating hormone therapy described the same class of reported effects (PMID 23884489). A separate review of EPP management placed those findings in the context of the condition's overall care (PMID 28003770). These are descriptions of what researchers observed in supervised clinical settings with an approved formulation, and they do not transfer to unapproved material of unknown provenance.

Regulatory Framing

Afamelanotide is an approved prescription medicine for erythropoietic protoporphyria in the jurisdictions discussed in the review literature (PMID 33507118, PMID 38784937). Powder sold under the informal name melanotan I with an RUO designation is a different thing: it is not an approved medicine, its labelling carries no therapeutic indication, and the clinical findings above were generated with the approved implant rather than with reconstituted research material. Understanding the arithmetic of concentration does not change that distinction.

References

• Pharmacokinetics and Pharmacodynamics of Afamelanotide and its Clinical Use in Treating Dermatologic Disorders (Clinical Pharmacokinetics, 2017)
• Afamelanotide: A Review in Erythropoietic Protoporphyria (American Journal of Clinical Dermatology, 2016)
• Afamelanotide for prevention of phototoxicity in erythropoietic protoporphyria (Expert Review of Clinical Pharmacology, 2021)
• Afamelanotide (CUV1647) in dermal phototoxicity of erythropoietic protoporphyria (Expert Review of Clinical Pharmacology, 2015)
• Afamelanotide, an agonistic analog of α-melanocyte-stimulating hormone, in dermal phototoxicity of erythropoietic protoporphyria (Expert Opinion on Investigational Drugs, 2010)
• Afamelanotide in protoporphyria and other skin diseases: a review (Postepy Dermatologii i Alergologii, 2024)
• Afamelanotide: An Orphan Drug with Potential for Broad Dermatologic Applications (Journal of Drugs in Dermatology, 2021)
• A review and update on melanocyte stimulating hormone therapy: afamelanotide (Journal of Drugs in Dermatology, 2013)
• Efficacy of the melanocortin analogue Nle4-D-Phe7-α-melanocyte-stimulating hormone in the treatment of patients with Hailey-Hailey disease (Clinical and Experimental Dermatology, 2014)
• Advances in the management of erythropoietic protoporphyria - role of afamelanotide (The Application of Clinical Genetics, 2016)